Page last updated: 2024-08-24

valsartan and aldosterone

valsartan has been researched along with aldosterone in 58 studies

Research

Studies (58)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's3 (5.17)18.2507
2000's30 (51.72)29.6817
2010's20 (34.48)24.3611
2020's5 (8.62)2.80

Authors

AuthorsStudies
Hayashi, N; Inukai, T; Kometani, M; Nakao, K; Yamamoto, S1
Clair, MJ; de Gasparo, M; Hebbar, L; Iannini, JP; Krombach, RS; Melton, DM; Mukherjee, R; O, SJ; Spinale, FG; Whitebread, S1
Chiang, YT; Gatlin, M; Glazer, R; Pool, JL1
Agarwal, R; Bakris, GL; Bolton, WK; Catanzaro, D; Hebert, L; Janssen, I; Richardson, D; Siomos, M1
Bieringer, M; Breu, V; Dechend, R; Fiebeler, A; Haller, H; Luft, FC; Müller, DN; Park, JK; Schmidt, F; Shagdarsuren, E1
Florin, M; Liu, KL; Lo, M; Sassard, J1
Miller, AB; Srivastava, P1
Bruneval, P; Clozel, JP; de Gasparo, M; Hess, P; Nuesslein-Hildesheim, B1
Andersson, OK; Elmfeldt, D; Friberg, PR; Fridman, KU; Wysocki, M1
Calvillo, L; De Angelis, N; Fiordaliso, F; Funicello, M; Gobbi, M; Latini, R; Masson, S; Mennini, T1
Düsing, R; Gohlke, P; Lottermoser, K; Unger, T; Vetter, H1
Anand, IS; Chiang, YT; Cohn, JN; Glazer, R; Latini, R; Masson, S1
Düsing, R; Lottermoser, K; Ulrich-Merzenich, G; Vetter, H1
Bedigian, MP; Lu, L; Robinson, AD; Sun, Y; Weber, KT; Zhang, J1
Hukai, D; Ishii, C; Kanamori, T; Ohbayashi, Y; Ohnishi, M; Ohno, K; Okabayashi, T; Ozawa, T; Sakaguchi, T; Sichiri, G; Tanaka, T; Tsutamoto, T; Tsutsui, T; Wada, A; Yokohama, H1
Anzai, T; Hashimoto, K; Himeno, H; Imai, K; Kawana, M; Kitakaze, M; Koretsune, Y; Maruyama, S; Masaoka, Y; Matsubara, H; Matsuoka, T; Miyao, Y; Miyatake, K; Miyauchi, T; Nakamura, Y; Nomura, F; Okamoto, H; Ozono, K; Sekiya, M; Shinohara, H; Shintani, U; Shiraki, T; Takaoka, H; Tsutamoto, T; Yasumura, Y; Yokoya, K; Yokoyama, H1
Crijns, HJ; Folkeringa, RJ; Pinto, YM1
Huang, CX; Jiang, H; Jiang, XJ; Liang, YH; Wang, JM; Zhou, Y1
Azizi, M; Bissery, A; Bura-Rivière, A; Camisasca, RP; Guyenne, TT; Ménard, J; Vaidyanathan, S1
He, Y; Savoia, C; Touyz, RM; Yao, G1
Siragy, HM; Xue, C1
Arbolishvili, GN; Baklanova, NA; Belenkov, IuN; Mareev, VIu; Nasonova, SN; Skvortsov, AA; Sychev, AV1
Higaki, J; Horiuchi, M; Iwai, M; Mogi, M; Oshita, A; Suzuki, J; Yoshii, T1
Baklanova, NA; Belenkov, IuN; Mareev, VIu; Masenko, VP; Nasonova, SN; Orlova, IaA; Skvortsov, AA; Sychev, AV1
Akdag, I; Filiz, G; Gullulu, M; Kahvecioglu, S; Savci, V1
Andronescu, D; Bengus, A; Dragomir, P; Fierbinteanu-Braticevici, C; Negreanu, L; Tribus, L; Usvat, R1
Jones, MR; Laragh, JH; Sealey, JE1
Fujita, T; Horiuchi, M; Iwai, M; Iwanami, J; Li, JM; Min, LJ; Mogi, M; Sakata, A; Tsukuda, K1
Karashima, S; Oda, N; Takata, H; Takeda, Y; Usukura, M; Yamagishi, M; Yamamoto, Y; Yoneda, T1
Kushibiki, M; Okumura, K; Osanai, T; Tomita, H; Yamada, M1
Akizuki, O; Inayoshi, A; Kitayama, T; Kusaka, H; Matsubara, M; Sasaki, K; Shirakura, S; Yao, K1
Elenkova, A; Kirilov, G; Lozanov, V; Mitev, V; Orbetzova, M; Shigarminova, R; Zacharieva, S1
Harbig, J; Jaworski, K; Miller, AG; Tan, G; Wilkinson-Berka, JL1
Adachi, M; Aritomi, S; Hayata, M; Kakizoe, Y; Kitamura, K; Ko, T; Konda, T; Miyoshi, T; Shiraishi, N; Tomita, K; Uchimura, K; Wakida, N1
Horiuchi, M; Iwanami, J; Jing, F; Min, LJ; Mogi, M; Ohshima, K; Sakata, A; Tsukuda, K1
Derbentseva, EA; Dralova, OV; Ermolaeva, AS; Maksimov, ML; Starodubtsev, AK1
Ferrario, CM; Habibi, J; Hayden, MR; Locher, B; Nistala, R; Pulakat, L; Sinak, C; Sowers, JR; Whaley-Connell, A1
Ebina, T; Hibi, K; Kimura, K; Kosuge, M; Kusama, I; Morita, S; Nozawa, N; Okuda, J; Ozaki, H; Tsukahara, K; Umemura, S; Yano, H1
Bugaj, V; Kohan, DE; Mironova, E; Ramkumar, N; Rees, S; Roos, KP; Stockand, JD1
Ardhanari, S; DeMarco, VG; Ferrario, CM; Habibi, J; Hayden, MR; Krueger, C; Pulakat, L; Rehmer, N; Sowers, JR; Whaley-Connell, A1
Bode, C; Braunwald, E; Brunel, PC; Hoffman, EB; Morrow, DA; Prescott, MF; Ren, F; Rifai, N; Scirica, BM; Swedberg, K; Udell, JA1
Born, J; Derad, I; Lehnert, H; Marshall, L; Nitschke, M; Sayk, F1
Bathgate-Siryk, A; Dabul, S; Garcia, D; Koch, WJ; Lymperopoulos, A; McDonald, P; Rengo, G; Sturchler, E; Walklett, K1
Bathgate-Siryk, A; Dabul, S; Jafferjee, M; Koch, WJ; Lymperopoulos, A; McDonald, P; Sturchler, E; Valero, TR1
Bakris, G; Bharucha, DB; Chen, C; Ferguson, WG; Giles, TD; Li, H; Mallick, M; Oparil, S; Weber, MA1
Albrecht, D; Averkov, O; Ayalasomayajula, S; Chandra, P; Jordaan, P; Kobalava, Z; Kotovskaya, Y; Langenickel, TH; Moiseev, V; Pal, P; Pavlikova, E; Prescott, MF; Rajman, I1
Fujii, M; Ichikawa, M; Imagawa, M; Ishizuka, T; Kaeriyama, S; Konoshita, T; Makino, Y; Nakamura, H; Nakaya, T; Sato, S; Suzuki, J; Urabe, M; Wakahara, S; Yamada, M; Yamamoto, K; Zenimaru, Y1
Chen, X; Gao, X; Lu, G; Luo, C; Luo, J; Peng, L; Zuo, Z1
Kitzman, DW; Packer, M1
Bislev, LS; Bjerregaard Pedersen, E; Langagergaard Rødbro, L; Nørgaard Bech, J; Rejnmark, L; Rolighed, L; Sikjaer, T1
Duran, SH; Jung, S; Newhard, DK; Winter, RL1
Danhof, M; Giraudel, J; Mochel, JP; Peyrou, M; Rigel, DF; Teng, CH1
Emdin, M; Passino, C; Vergaro, G1
Alba, PR; Bress, AP; Choi, ME; Cook, J; Dodson, JA; Fang, JC; He, T; Herrick, JS; King, JB; Levitan, EB; Mohanty, AF; Obi, EN; Patterson, OV; Russo, PA; Vardeny, O1
Al-Gareeb, AI; Al-Kuraishy, HM; Alexiou, A; Batiha, GE1
Crespo-Leiro, MG; Escobar, C; Esteban-Fernández, A; Farré, N; Garcia, A; Luis-Bonilla, J; Nuñez, J1
Babes, EE; Behl, T; Bungau, SG; Horvath, T; Iovanovici, DC; Moisi, M; Rus, M; Tit, DM; Vesa, CM1
Handa, T; Ikushima, A; Inoue, Y; Ishii, A; Ishimura, T; Kato, Y; Minamino, N; Mori, KP; Mukoyama, M; Nishio, H; Ohno, S; Sugioka, S; Yamada, H; Yanagita, M; Yokoi, H1

Reviews

3 review(s) available for valsartan and aldosterone

ArticleYear
Angiotensin receptor blockers and aldosterone antagonists in chronic heart failure.
    Cardiology clinics, 2001, Volume: 19, Issue:2

    Topics: Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Captopril; Heart Failure; Humans; Hypertension; Losartan; Mineralocorticoid Receptor Antagonists; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan

2001
Obesity-Related Heart Failure With a Preserved Ejection Fraction: The Mechanistic Rationale for Combining Inhibitors of Aldosterone, Neprilysin, and Sodium-Glucose Cotransporter-2.
    JACC. Heart failure, 2018, Volume: 6, Issue:8

    Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Benzhydryl Compounds; Biphenyl Compounds; Drug Combinations; Drug Therapy, Combination; Glucosides; Heart Failure; Humans; Mineralocorticoid Receptor Antagonists; Neprilysin; Obesity; Plasma Volume; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Tetrazoles; Valsartan

2018
Reviewing the Modern Therapeutical Options and the Outcomes of Sacubitril/Valsartan in Heart Failure.
    International journal of molecular sciences, 2022, Sep-26, Volume: 23, Issue:19

    Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Drug Combinations; Enalapril; Heart Failure; Humans; Natriuretic Peptides; Neprilysin; Prospective Studies; Quality of Life; Renin; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left

2022

Trials

20 trial(s) available for valsartan and aldosterone

ArticleYear
Dose-response efficacy of valsartan, a new angiotensin II receptor blocker.
    Journal of human hypertension, 1999, Volume: 13, Issue:4

    Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Female; Follow-Up Studies; Humans; Hypertension; Male; Middle Aged; Posture; Renin; Tetrazoles; Treatment Outcome; Valine; Valsartan

1999
ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group.
    Kidney international, 2000, Volume: 58, Issue:5

    Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cross-Over Studies; Female; Glomerular Filtration Rate; Humans; Kidney; Lisinopril; Male; Middle Aged; Potassium; Renal Insufficiency; Tetrazoles; Valine; Valsartan

2000
Influence of AT1 receptor blockade on blood pressure, renal haemodynamics and hormonal responses to intravenous angiotensin II infusion in hypertensive patients.
    Blood pressure, 2002, Volume: 11, Issue:4

    Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Cross-Over Studies; Double-Blind Method; Drug Therapy, Combination; Female; Hemodynamics; Humans; Hypertension; Infusions, Intravenous; Losartan; Male; Middle Aged; Receptor, Angiotensin, Type 1; Renal Circulation; Renin; Tetrazoles; Valine; Valsartan

2002
Differential effect of acute angiotensin II type 1 receptor blockade on the vascular and adrenal response to exogenous angiotensin II in humans.
    American journal of hypertension, 2003, Volume: 16, Issue:6

    Topics: Adrenal Glands; Adult; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Endothelins; Heart Rate; Humans; Hydrocortisone; Injections, Intravenous; Interleukin-6; Male; Renin; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan; Vasoconstrictor Agents

2003
Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial.
    Circulation, 2003, Sep-16, Volume: 108, Issue:11

    Topics: Aldosterone; Angiotensin Receptor Antagonists; Cardiac Output, Low; Chronic Disease; Double-Blind Method; Follow-Up Studies; Humans; Tetrazoles; Valine; Valsartan

2003
[Effects of angiotensin II on inflammation mediators in healthy subjects].
    Deutsche medizinische Wochenschrift (1946), 2003, Nov-21, Volume: 128, Issue:47

    Topics: Adult; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Cytokines; Humans; Inflammation Mediators; Interleukin-6; Male; Renin-Angiotensin System; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan; Vascular Cell Adhesion Molecule-1

2003
Effect of an angiotensin II type 1 receptor blocker, valsartan, on neurohumoral factors in patients with hypertension: comparison with a long-acting calcium channel antagonist, amlodipine.
    Journal of cardiovascular pharmacology, 2003, Volume: 42 Suppl 1

    Topics: Aged; Aldosterone; Amlodipine; Angiotensin II Type 1 Receptor Blockers; Calcium Channel Blockers; Coronary Disease; Delayed-Action Preparations; Female; Heart Failure; Humans; Hypertension; Male; Middle Aged; Natriuretic Peptide, Brain; Neurotransmitter Agents; Norepinephrine; Receptor, Angiotensin, Type 1; Tetrazoles; Time Factors; Valine; Valsartan

2003
Rationale for the use of combination angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker therapy in heart failure.
    Circulation journal : official journal of the Japanese Circulation Society, 2004, Volume: 68, Issue:4

    Topics: Adrenergic beta-Antagonists; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Benzimidazoles; Biphenyl Compounds; Drug Synergism; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Failure; Heart Function Tests; Humans; Losartan; Male; Middle Aged; Natriuretic Peptide, Brain; Receptors, Angiotensin; Renin; Tetrazoles; Valine; Valsartan

2004
Pharmacologic demonstration of the synergistic effects of a combination of the renin inhibitor aliskiren and the AT1 receptor antagonist valsartan on the angiotensin II-renin feedback interruption.
    Journal of the American Society of Nephrology : JASN, 2004, Volume: 15, Issue:12

    Topics: Administration, Oral; Adolescent; Adult; Aldosterone; Amides; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Drug Synergism; Feedback, Physiological; Fumarates; Humans; Male; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

2004
[Combined therapy with quinapril, an ACE inhibitor, and valsartan, a type 1 angiotensin II receptors blocker, for moderate chronic cardiac failure may raise the degree of neurohormonal block and improve 24-h heart rate variability compared to the effect o
    Terapevticheskii arkhiv, 2005, Volume: 77, Issue:8

    Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Chronic Disease; Drug Therapy, Combination; Electrocardiography, Ambulatory; Female; Heart Failure; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Quinapril; Renin; Tetrahydroisoquinolines; Tetrazoles; Valine; Valsartan

2005
[Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADK
    Kardiologiia, 2006, Volume: 46, Issue:7

    Topics: Adult; Aged; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiac Output, Low; Chronic Disease; Drug Therapy, Combination; Exercise Tolerance; Female; Heart Rate; Humans; Male; Middle Aged; Norepinephrine; Quinapril; Tetrahydroisoquinolines; Tetrazoles; Treatment Outcome; Valine; Valsartan; Ventricular Remodeling

2006
The effect of valsartan, an angiotensin II receptor antagonist, on portal and systemic hemodynamics and on renal function in liver cirrhosis.
    Journal of gastrointestinal and liver diseases : JGLD, 2006, Volume: 15, Issue:4

    Topics: Adult; Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Biomarkers; Creatinine; Female; Hemodynamics; Humans; Hypertension, Portal; Kidney; Liver Cirrhosis; Male; Metanephrine; Middle Aged; Natriuresis; Portal System; Renin; Romania; Single-Blind Method; Sodium; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan

2006
Effects of angiotensin receptor blockers on ambulatory plasma Renin activity in healthy, normal subjects during unrestricted sodium intake.
    American journal of hypertension, 2007, Volume: 20, Issue:8

    Topics: Adolescent; Adult; Aged; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Biomarkers; Biphenyl Compounds; Blood Pressure; Circadian Rhythm; Cross-Over Studies; Dose-Response Relationship, Drug; Female; Follow-Up Studies; Humans; Imidazoles; Irbesartan; Male; Middle Aged; Olmesartan Medoxomil; Prognosis; Radioimmunoassay; Reference Values; Renin; Renin-Angiotensin System; Single-Blind Method; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan

2007
Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
    American journal of hypertension, 2007, Volume: 20, Issue:12

    Topics: Aged; Albuminuria; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Nephropathies; Female; Humans; Hypertension; Male; Middle Aged; Tetrazoles; Valine; Valsartan

2007
Effects of valsartan, an angiotensin II receptor blocker, on coronary atherosclerosis in patients with acute myocardial infarction who receive an angiotensin-converting enzyme inhibitor.
    Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:6

    Topics: Aged; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Blood Pressure; Captopril; Chi-Square Distribution; Coronary Artery Disease; Drug Therapy, Combination; Female; Humans; Hypertrophy, Left Ventricular; Japan; Logistic Models; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Odds Ratio; Predictive Value of Tests; Prospective Studies; Renin-Angiotensin System; Risk Assessment; Risk Factors; Tetrazoles; Time Factors; Treatment Outcome; Ultrasonography, Interventional; Valine; Valsartan

2012
Intranasal angiotensin II in humans reduces blood pressure when angiotensin II type 1 receptors are blocked.
    Hypertension (Dallas, Tex. : 1979), 2014, Volume: 63, Issue:4

    Topics: Administration, Intranasal; Adult; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Cross-Over Studies; Double-Blind Method; Female; Heart Rate; Humans; Hydrocortisone; Male; Receptor, Angiotensin, Type 1; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

2014
Correlations of plasma renin activity and aldosterone concentration with ambulatory blood pressure responses to nebivolol and valsartan, alone and in combination, in hypertension.
    Journal of the American Society of Hypertension : JASH, 2015, Volume: 9, Issue:11

    Topics: Aldosterone; Blood Pressure Monitoring, Ambulatory; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Hypertension; Male; Maximum Tolerated Dose; Nebivolol; Patient Selection; Renin; Renin-Angiotensin System; Risk Assessment; Severity of Illness Index; Treatment Outcome; Valsartan

2015
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
    Cardiovascular therapeutics, 2016, Volume: 34, Issue:4

    Topics: Aged; Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Area Under Curve; Biomarkers; Biphenyl Compounds; Chronic Disease; Drug Administration Schedule; Drug Combinations; Endothelin-1; Female; Heart Failure; Humans; Male; Middle Aged; Natriuretic Peptide, Brain; Neprilysin; Peptide Fragments; Renin-Angiotensin System; Russia; Stroke Volume; Tetrazoles; Treatment Outcome; Valsartan; Ventricular Function, Left

2016
Effects of treatment with an angiotensin 2 receptor blocker and/or vitamin D3 on parathyroid hormone and aldosterone: A randomized, placebo-controlled trial.
    Clinical endocrinology, 2018, Volume: 89, Issue:5

    Topics: Aged; Aldosterone; Angiotensin Receptor Antagonists; Blood Pressure; Cholecalciferol; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Parathyroid Hormone; Postmenopause; Valsartan; Vitamin D Deficiency

2018
A prospective, randomized, double-blind, placebo-controlled pilot study of sacubitril/valsartan (Entresto) in dogs with cardiomegaly secondary to myxomatous mitral valve disease.
    Journal of veterinary internal medicine, 2018, Volume: 32, Issue:5

    Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Blood Pressure; Blood Urea Nitrogen; Cardiomegaly; Creatinine; Dog Diseases; Dogs; Double-Blind Method; Drug Combinations; Electrolytes; Female; Male; Mitral Valve Insufficiency; Pilot Projects; Random Allocation; Tetrazoles; Valsartan

2018

Other Studies

35 other study(ies) available for valsartan and aldosterone

ArticleYear
Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
    Arzneimittel-Forschung, 1997, Volume: 47, Issue:5

    Topics: Aldosterone; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Blood Pressure; Desoxycorticosterone; Dogs; Enalapril; Heart Rate; Hypertension; Hypertension, Renal; Male; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rats, Wistar; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Renin; Tetrazoles; Valine; Valsartan

1997
Modulation of the renin-angiotensin pathway through enzyme inhibition and specific receptor blockade in pacing-induced heart failure: I. Effects on left ventricular performance and neurohormonal systems.
    Circulation, 1997, Oct-07, Volume: 96, Issue:7

    Topics: Aldosterone; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Benzazepines; Blood Pressure; Cardiac Output; Cardiac Pacing, Artificial; Diastole; Disease Models, Animal; Endothelins; Epinephrine; Heart Failure; Heart Rate; Hemodynamics; Norepinephrine; Pulmonary Artery; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Renin; Renin-Angiotensin System; Swine; Tetrazoles; Valine; Valsartan; Ventricular Function, Left

1997
Mineralocorticoid receptor affects AP-1 and nuclear factor-kappab activation in angiotensin II-induced cardiac injury.
    Hypertension (Dallas, Tex. : 1979), 2001, Volume: 37, Issue:2 Pt 2

    Topics: Aldosterone; Angiotensin II; Animals; Animals, Genetically Modified; Blood Pressure; Body Weight; Cardiovascular Diseases; Fibroblast Growth Factor 2; Heart; Immunohistochemistry; Mineralocorticoid Receptor Antagonists; NF-kappa B; Organ Size; Platelet-Derived Growth Factor; Rats; Receptors, Mineralocorticoid; Renin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Spironolactone; Tetrazoles; Transcription Factor AP-1; Transforming Growth Factor beta; Valine; Valsartan

2001
Salt sensitivity in genetically hypertensive rats of the Lyon strain.
    Kidney international, 2001, Volume: 59, Issue:5

    Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Drug Resistance; Hypertension; Kidney; Male; Perindopril; Rats; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan

2001
Combination of non-hypotensive doses of valsartan and enalapril improves survival of spontaneously hypertensive rats with endothelial dysfunction.
    Journal of the renin-angiotensin-aldosterone system : JRAAS, 2000, Volume: 1, Issue:2

    Topics: Aldosterone; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Creatinine; Dose-Response Relationship, Drug; Drug Combinations; Enalapril; Endothelium, Vascular; Hypertension; Male; Rats; Rats, Inbred SHR; Survival Analysis; Tetrazoles; Valine; Valsartan

2000
Appraisal of the role of angiotensin II and aldosterone in ventricular myocyte apoptosis in adult normotensive rat.
    Journal of molecular and cellular cardiology, 2002, Volume: 34, Issue:12

    Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin II Type 2 Receptor Blockers; Angiotensin Receptor Antagonists; Animals; Apoptosis; Cell Nucleus; Cells, Cultured; Down-Regulation; Heart Ventricles; Male; Myocytes, Cardiac; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Receptor, Angiotensin, Type 2; Receptors, Angiotensin; Tetrazoles; Valine; Valsartan

2002
Tissue angiotensin II in the regulation of inflammatory and fibrogenic components of repair in the rat heart.
    The Journal of laboratory and clinical medicine, 2004, Volume: 143, Issue:1

    Topics: Aldosterone; Angiotensin II; Animals; Cardiomegaly; Collagen Type I; Disease Models, Animal; Drug Therapy, Combination; Fibrosis; Heart; In Situ Hybridization; Infusions, Parenteral; Male; Myocardium; Nephrectomy; NF-kappa B; Rats; Rats, Sprague-Dawley; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan

2004
Aldosterone levels after angiotensin receptor blocker treatment.
    Circulation, 2004, Apr-13, Volume: 109, Issue:14

    Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Disease Progression; Heart Failure; Humans; Tetrazoles; Valine; Valsartan

2004
Additive effects of combined valsartan and spironolactone on cardiac aldosterone escape in spontaneously hypertensive rats.
    Life sciences, 2004, Aug-27, Volume: 75, Issue:15

    Topics: Aldosterone; Animals; Antihypertensive Agents; Blood Pressure; Body Weight; Central Venous Pressure; Chromatography, High Pressure Liquid; Collagen; Heart; Hydroxyproline; Male; Mineralocorticoid Receptor Antagonists; Myocardium; Organ Size; Rats; Rats, Inbred SHR; Renin-Angiotensin System; Spironolactone; Tetrazoles; Valine; Valsartan

2004
Transient receptor potential melastatin 7 ion channels regulate magnesium homeostasis in vascular smooth muscle cells: role of angiotensin II.
    Circulation research, 2005, Feb-04, Volume: 96, Issue:2

    Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cell Division; Cells, Cultured; DNA Replication; Gene Expression Regulation; Homeostasis; Humans; Ion Channels; Ion Transport; Magnesium; Membrane Proteins; Mice; Mice, Inbred C57BL; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Protein Biosynthesis; Protein Kinases; Protein Serine-Threonine Kinases; Rats; Rats, Inbred WKY; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; RNA, Small Interfering; Tetrazoles; Transfection; TRPM Cation Channels; Valine; Valsartan

2005
Local renal aldosterone system and its regulation by salt, diabetes, and angiotensin II type 1 receptor.
    Hypertension (Dallas, Tex. : 1979), 2005, Volume: 46, Issue:3

    Topics: Adrenalectomy; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Cytochrome P-450 CYP11B2; Cytochrome P-450 Enzyme System; Diabetes Mellitus, Experimental; Dose-Response Relationship, Drug; Insulin; Kidney; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; RNA, Messenger; Sodium Chloride; Steroid Hydroxylases; Tetrazoles; Tissue Distribution; Valine; Valsartan

2005
Eplerenone with valsartan effectively reduces atherosclerotic lesion by attenuation of oxidative stress and inflammation.
    Arteriosclerosis, thrombosis, and vascular biology, 2006, Volume: 26, Issue:4

    Topics: Aldosterone; Animals; Aorta; Atherosclerosis; Blood Pressure; Cells, Cultured; Chemokine CCL2; Cholesterol, Dietary; Diet, Atherogenic; Enzyme Activation; Eplerenone; Inflammation; Male; Mice; Muscle, Smooth, Vascular; NADPH Oxidases; Oxidative Stress; Spironolactone; Superoxides; Tetrazoles; Tumor Necrosis Factor-alpha; Valine; Valsartan

2006
Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well.
    Renal failure, 2006, Volume: 28, Issue:6

    Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Cell Proliferation; Disease Models, Animal; Diuretics; Fibrosis; Glomerulonephritis, Membranoproliferative; Ki-67 Antigen; Kidney; Mineralocorticoid Receptor Antagonists; Rats; Rats, Sprague-Dawley; Spironolactone; Tetrazoles; Transforming Growth Factor beta; Valine; Valsartan

2006
Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence.
    Cardiovascular research, 2007, Dec-01, Volume: 76, Issue:3

    Topics: Aldosterone; Angiotensin II; Animals; Aorta, Thoracic; beta-Galactosidase; Cells, Cultured; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor p21; Dose-Response Relationship, Drug; Male; Muscle, Smooth, Vascular; Oxidative Stress; Proto-Oncogene Proteins p21(ras); Rats; Rats, Sprague-Dawley; Receptor Cross-Talk; Renin-Angiotensin System; RNA, Small Interfering; Spironolactone; Tetrazoles; Tumor Suppressor Protein p53; Valine; Valsartan

2007
Vasoconstrictor effect of aldosterone via angiotensin II type 1 (AT1) receptor: possible role of AT1 receptor dimerization.
    Cardiovascular research, 2008, Jul-01, Volume: 79, Issue:1

    Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Arterioles; Benzimidazoles; Biphenyl Compounds; Dimerization; Eplerenone; Male; Mesentery; Mice; Mice, Inbred C57BL; Mice, Knockout; Mineralocorticoid Receptor Antagonists; Receptor, Angiotensin, Type 1; Spironolactone; Tetrazoles; Transglutaminases; Valine; Valsartan; Vasoconstriction; Vasodilation

2008
Blockade of T-type voltage-dependent Ca2+ channels by benidipine, a dihydropyridine calcium channel blocker, inhibits aldosterone production in human adrenocortical cell line NCI-H295R.
    European journal of pharmacology, 2008, Apr-28, Volume: 584, Issue:2-3

    Topics: Adrenal Cortex; Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Calcium; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, T-Type; Cell Line; Cytochrome P-450 CYP11B2; Dihydropyridines; Dose-Response Relationship, Drug; Gene Expression Regulation, Enzymologic; Humans; Membrane Potentials; Patch-Clamp Techniques; Potassium Chloride; RNA, Messenger; Steroid 11-beta-Hydroxylase; Tetrazoles; Valine; Valsartan

2008
Homocysteine, renin and aldosterone in patients with Cushing's syndrome.
    Methods and findings in experimental and clinical pharmacology, 2008, Volume: 30, Issue:3

    Topics: Adult; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Chromatography, High Pressure Liquid; Cushing Syndrome; Female; Fluorescence Polarization Immunoassay; Homocysteine; Humans; Male; Metabolic Syndrome; Renin; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

2008
Identification of a retinal aldosterone system and the protective effects of mineralocorticoid receptor antagonism on retinal vascular pathology.
    Circulation research, 2009, 01-02, Volume: 104, Issue:1

    Topics: Aldosterone; Angiogenesis Inhibitors; Angiotensin II Type 1 Receptor Blockers; Animals; Cattle; Cells, Cultured; Cytokines; Endothelial Cells; Eye Proteins; Glucosephosphate Dehydrogenase; Leukostasis; Mineralocorticoid Receptor Antagonists; NADPH Oxidase 4; NADPH Oxidases; Neovascularization, Pathologic; Oxidative Stress; Oxygen; Pericytes; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Renin-Angiotensin System; Retinal Vasculitis; Sodium Chloride; Spironolactone; Tetrazoles; Valine; Valsartan; Vascular Endothelial Growth Factor A

2009
Regulation of adrenal aldosterone production by serine protease prostasin.
    Journal of biomedicine & biotechnology, 2010, Volume: 2010

    Topics: Adrenal Cortex; Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Calcium Channel Blockers; Cell Line; Cytochrome P-450 CYP11B2; Dihydropyridines; Gene Expression Regulation; Gene Silencing; Humans; Nitrophenols; Organophosphorus Compounds; Promoter Regions, Genetic; Rats; Receptors, Proteinase-Activated; Recombinant Proteins; Serine Endopeptidases; Tetrazoles; Transfection; Valine; Valsartan

2010
Angiotensin II and aldosterone-induced neuronal damage in neurons through an astrocyte-dependent mechanism.
    Hypertension research : official journal of the Japanese Society of Hypertension, 2011, Volume: 34, Issue:6

    Topics: Aldosterone; Angiotensin II; Animals; Astrocytes; Cells, Cultured; DNA Damage; Eplerenone; Ganglia, Spinal; Mice; Mice, Inbred C57BL; Receptor, Angiotensin, Type 1; Receptors, Mineralocorticoid; Spironolactone; Tetrazoles; Valine; Valsartan

2011
[Correction of aldosterone level as marker of RAAS dysfunction in patients with arterial hypertension degree II-III and chronic kidney diseases].
    Eksperimental'naia i klinicheskaia farmakologiia, 2011, Volume: 74, Issue:4

    Topics: Aged; Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Biomarkers; Drug Therapy, Combination; Enalapril; Female; Fumarates; Humans; Hypertension; Indapamide; Male; Middle Aged; Mineralocorticoid Receptor Antagonists; Randomized Controlled Trials as Topic; Renal Insufficiency, Chronic; Renin-Angiotensin System; Tetrazoles; Valine; Valsartan

2011
Combination of direct renin inhibition with angiotensin type 1 receptor blockade improves aldosterone but does not improve kidney injury in the transgenic Ren2 rat.
    Regulatory peptides, 2012, Jun-10, Volume: 176, Issue:1-3

    Topics: Acute Kidney Injury; Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Fumarates; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Renin; Tetrazoles; Valine; Valsartan

2012
Adenylyl cyclase VI mediates vasopressin-stimulated ENaC activity.
    Journal of the American Society of Nephrology : JASN, 2013, Volume: 24, Issue:2

    Topics: Adenylyl Cyclases; Aldosterone; Animals; Antidiuretic Agents; Antihypertensive Agents; Aquaporin 2; Arginine Vasopressin; Blood Pressure; Epithelial Sodium Channels; Female; Heart Rate; Kidney Tubules, Collecting; Male; Mice; Mice, Knockout; Patch-Clamp Techniques; Renin; Sodium; Sodium Chloride, Dietary; Tetrazoles; Valine; Valsartan

2013
Renin inhibition and AT(1)R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling.
    Metabolism: clinical and experimental, 2013, Volume: 62, Issue:6

    Topics: Aldosterone; Amides; Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cell Size; Drug Interactions; Fibrosis; Fumarates; Mice; Myocardium; Myocytes, Cardiac; Oxidative Stress; Rats; Rats, Sprague-Dawley; Rats, Transgenic; Receptor, Angiotensin, Type 1; Renin; Signal Transduction; Tetrazoles; Valine; Valsartan; Ventricular Remodeling

2013
Inhibition of the renin-angiotensin system reduces the rise in serum aldosterone in acute coronary syndrome patients with preserved left ventricular function: observations from the AVANT GARDE-TIMI 43 trial.
    Clinical chemistry, 2013, Volume: 59, Issue:6

    Topics: Acute Coronary Syndrome; Aldosterone; Amides; Angiotensin-Converting Enzyme Inhibitors; Down-Regulation; Female; Fumarates; Humans; Male; Middle Aged; Renin-Angiotensin System; Retrospective Studies; Tetrazoles; Valine; Valsartan; Ventricular Function, Left

2013
Different potencies of angiotensin receptor blockers at suppressing adrenal β-Arrestin1-dependent post-myocardial infarction hyperaldosteronism.
    Journal of the American College of Cardiology, 2014, Dec-30, Volume: 64, Issue:25

    Topics: Aldosterone; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazoles; Biphenyl Compounds; Hyperaldosteronism; Myocardial Infarction; Rats; Tetrazoles; Valine; Valsartan

2014
Suppression of adrenal βarrestin1-dependent aldosterone production by ARBs: head-to-head comparison.
    Scientific reports, 2015, Jan-29, Volume: 5

    Topics: Adrenal Glands; Aldosterone; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Arrestins; Benzimidazoles; beta-Arrestins; Biphenyl Compounds; CHO Cells; Cricetinae; Cricetulus; GTP-Binding Proteins; Humans; Phosphoproteins; Rats; Receptor, Angiotensin, Type 1; Tetrazoles; Up-Regulation; Valine; Valsartan; Zona Glomerulosa

2015
On the top of ARB N/L type Ca channel blocker leads to less elevation of aldosterone.
    Bioscience reports, 2016, Volume: 36, Issue:5

    Topics: Aged; Aldosterone; Amlodipine; Angiotensin Receptor Antagonists; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Calcium Channels, N-Type; Dihydropyridines; Drug Combinations; Female; Humans; Hypertension; Male; Middle Aged; Renin-Angiotensin System; Valsartan

2016
Hydrochlorothiazide modulates ischemic heart failure-induced cardiac remodeling via inhibiting angiotensin II type 1 receptor pathway in rats.
    Cardiovascular therapeutics, 2017, Volume: 35, Issue:2

    Topics: Aldosterone; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Animals, Newborn; Cells, Cultured; Disease Models, Animal; Diuretics; Fibroblasts; Fibrosis; Furosemide; Heart Failure; Heart Ventricles; Hydrochlorothiazide; Male; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Recovery of Function; Signal Transduction; Smad2 Protein; Stroke Volume; Transforming Growth Factor beta1; Valsartan; Ventricular Function, Left; Ventricular Remodeling

2017
Sacubitril/valsartan (LCZ696) significantly reduces aldosterone and increases cGMP circulating levels in a canine model of RAAS activation.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2019, Feb-01, Volume: 128

    Topics: Aldosterone; Aminobutyrates; Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Animals; Biphenyl Compounds; Cross-Over Studies; Cyclic GMP; Dogs; Dose-Response Relationship, Drug; Drug Combinations; Female; Heart Failure; Humans; Male; Natriuretic Peptides; Renin-Angiotensin System; Sodium, Dietary; Tetrazoles; Valsartan

2019
No Aldosterone Breakthrough With the Neprilysin Inhibitor Sacubitril.
    Journal of the American College of Cardiology, 2019, 06-18, Volume: 73, Issue:23

    Topics: Aldosterone; Aminobutyrates; Biphenyl Compounds; Drug Combinations; Extracellular Matrix; Heart Failure; Humans; Neprilysin; Stroke Volume; Tetrazoles; Valsartan

2019
Sacubitril/Valsartan Initiation Among Veterans Who Are Renin-Angiotensin-Aldosterone System Inhibitor Naïve With Heart Failure and Reduced Ejection Fraction.
    Journal of the American Heart Association, 2021, 10-19, Volume: 10, Issue:20

    Topics: Aldosterone; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Biphenyl Compounds; Heart Failure; Humans; Renin-Angiotensin System; Retrospective Studies; Stroke Volume; Tetrazoles; Valsartan; Ventricular Function, Left; Veterans

2021
Targeting and Modulation of the Natriuretic Peptide System in Covid-19: A Single or Double-Edged Effect?
    Current protein & peptide science, 2022, Volume: 23, Issue:5

    Topics: Aldosterone; Aminobutyrates; Anti-Inflammatory Agents; Atrial Natriuretic Factor; Biphenyl Compounds; Cathepsin G; COVID-19 Drug Treatment; Cytokines; Gastrin-Releasing Peptide; Heart Failure; Humans; Natriuretic Peptide, Brain; Natriuretic Peptides; Neprilysin; Renin; Respiratory Distress Syndrome; Tetrazoles; Valsartan

2022
Individualizing the treatment of patients with heart failure with reduced ejection fraction: a journey from hospitalization to long-term outpatient care.
    Expert opinion on pharmacotherapy, 2022, Volume: 23, Issue:14

    Topics: Aldosterone; Ambulatory Care; Aminobutyrates; Angiotensin Receptor Antagonists; Angiotensins; Biphenyl Compounds; Guanylate Cyclase; Heart Failure; Hospitalization; Humans; Ivabradine; Natriuretic Peptides; Potassium; Renin; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Stroke Volume; Valsartan

2022
Sacubitril/valsartan ameliorates renal tubulointerstitial injury through increasing renal plasma flow in a mouse model of type 2 diabetes with aldosterone excess.
    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2023, Oct-31, Volume: 38, Issue:11

    Topics: Aldosterone; Animals; Biphenyl Compounds; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fibrosis; Kidney; Male; Mice; Natriuretic Peptides; Renal Plasma Flow; Valsartan

2023